Heart Fatty Acid-binding Protein is Associated with Phosphorylated Tau and Longitudinal Cognitive Changes

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Oct 27

PMID 36299612

Authors

Yan Fu

Zuo-Teng Wang

Liang-Yu Huang

Chen-Chen Tan

Xi-Peng Cao

Lan Tan

Affiliations

Soon will be listed here.

Abstract

Background: Perturbation of lipid metabolism is associated with Alzheimer's disease (AD). Heart fatty acid-binding protein (HFABP) is an adipokine playing an important role in lipid metabolism regulation.

Materials And Methods: Two datasets separately enrolled 303 and 197 participants. First, we examine the associations of cerebrospinal fluid (CSF) HFABP levels with cognitive measures [including Mini-Mental State Examination (MMSE), Clinical Dementia Rating sum of boxes (CDRSB), and the cognitive section of Alzheimer's Disease Assessment Scale] and AD biomarkers (CSF amyloid beta and tau levels). Second, we examine the longitudinal associations of baseline CSF HFABP levels and the variability of HFABP with cognitive measures and AD biomarkers. Structural equation models explored the mediation effects of AD pathologies on cognition.

Results: We found a significant relationship between CSF HFABP level and P-tau (dataset 1: β = 2.04, < 0.001; dataset 2: β = 1.51, < 0.001). We found significant associations of CSF HFABP with longitudinal cognitive measures (dataset 1: ADAS13, β = 0.09, = 0.008; CDRSB, β = 0.10, = 0.003; MMSE, β = -0.15, < 0.001; dataset 2: ADAS13, β = 0.07, = 0.004; CDRSB, β = 0.07, = 0.005; MMSE, β = -0.09, < 0.001) in longitudinal analysis. The variability of HFABP was associated with CSF P-tau (dataset 2: β = 3.62, = 0.003). Structural equation modeling indicated that tau pathology mediated the relationship between HFABP and cognition.

Conclusion: Our findings demonstrated that HFABP was significantly associated with longitudinal cognitive changes, which might be partially mediated by tau pathology.

Citing Articles

SERS-Based Optical Nanobiosensors for the Detection of Alzheimer's Disease.

Gao F, Li F, Wang J, Yu H, Li X, Chen H Biosensors (Basel). 2023; 13(9).

PMID: 37754114 PMC: 10526933. DOI: 10.3390/bios13090880.

References

Hooper N . Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans. 2005; 33(Pt 2):335-8. DOI: 10.1042/BST0330335. View

Matsuo K, Yabuki Y, Melki R, Bousset L, Owada Y, Fukunaga K . Crucial Role of FABP3 in αSyn-Induced Reduction of Septal GABAergic Neurons and Cognitive Decline in Mice. Int J Mol Sci. 2021; 22(1). PMC: 7795765. DOI: 10.3390/ijms22010400. View

Yabuki Y, Matsuo K, Kawahata I, Fukui N, Mizobata T, Kawata Y . Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain. Int J Mol Sci. 2020; 21(6). PMC: 7139546. DOI: 10.3390/ijms21062230. View

Fortin D, Troyer M, Nakamura K, Kubo S, Anthony M, Edwards R . Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci. 2004; 24(30):6715-23. PMC: 6729723. DOI: 10.1523/JNEUROSCI.1594-04.2004. View

Siino V, Amato A, Di Salvo F, Caldara G, Filogamo M, James P . Impact of diet-induced obesity on the mouse brain phosphoproteome. J Nutr Biochem. 2018; 58:102-109. DOI: 10.1016/j.jnutbio.2018.04.015. View

Desikan R, Thompson W, Holland D, Hess C, Brewer J, Zetterberg H . Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration. Mol Neurodegener. 2013; 8:39. PMC: 3850652. DOI: 10.1186/1750-1326-8-39. View

Weiner M, Veitch D, Aisen P, Beckett L, Cairns N, Green R . The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2011; 8(1 Suppl):S1-68. PMC: 3329969. DOI: 10.1016/j.jalz.2011.09.172. View

Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S . Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimers Res Ther. 2017; 9(1):52. PMC: 5532764. DOI: 10.1186/s13195-017-0276-4. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

10.

Dulewicz M, Kulczynska-Przybik A, Slowik A, Borawska R, Mroczko B . Fatty Acid Binding Protein 3 (FABP3) and Apolipoprotein E4 (ApoE4) as Lipid Metabolism-Related Biomarkers of Alzheimer's Disease. J Clin Med. 2021; 10(14). PMC: 8303862. DOI: 10.3390/jcm10143009. View

11.

Taylor D, Hooper N . Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin Cell Dev Biol. 2007; 18(5):638-48. DOI: 10.1016/j.semcdb.2007.07.008. View

12.

Clark A, Haley A, Duarte A, OBryant S . Fatty Acid-Binding Protein 3 Is a Marker of Neurodegeneration and White Matter Hyperintensity Burden in Mexican American Older Adults. J Alzheimers Dis. 2022; 90(1):61-68. PMC: 11234903. DOI: 10.3233/JAD-220524. View

13.

Vidal-Pineiro D, Sorensen O, Blennow K, Capogna E, Halaas N, Idland A . Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. Neurobiol Aging. 2022; 116:80-91. DOI: 10.1016/j.neurobiolaging.2022.04.010. View

14.

Papsdorf K, Brunet A . Linking Lipid Metabolism to Chromatin Regulation in Aging. Trends Cell Biol. 2018; 29(2):97-116. PMC: 6340780. DOI: 10.1016/j.tcb.2018.09.004. View

15.

Mauch D, Nagler K, Schumacher S, Goritz C, Muller E, Otto A . CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001; 294(5545):1354-7. DOI: 10.1126/science.294.5545.1354. View

16.

Rosen C, Mattsson N, Johansson P, Andreasson U, Wallin A, Hansson O . Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Front Aging Neurosci. 2011; 3:1. PMC: 3057441. DOI: 10.3389/fnagi.2011.00001. View

17.

Mori T, Paris D, Town T, Rojiani A, Sparks D, Delledonne A . Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol. 2001; 60(8):778-85. DOI: 10.1093/jnen/60.8.778. View

18.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

19.

Guo L, Alexopoulos P, Perneczky R . Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2013; 263(7):553-60. DOI: 10.1007/s00406-013-0405-4. View

20.

Kirkitadze M, Bitan G, Teplow D . Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res. 2002; 69(5):567-77. DOI: 10.1002/jnr.10328. View